Flow Cytometry in Oncology and Immunology Global Market Report 2022: Innovation in Flow Cytometry Leading to Use of Next-Generation Flow Cytometers
November 29, 2022 04:03 ET | Research and Markets
Dublin, Nov. 29, 2022 (GLOBE NEWSWIRE) -- The "Flow Cytometry in Oncology and Immunology Market - A Global Market and Regional: Focus on Offering, Technology, End User, Type, Application, and...
The Worldwide Interventional Oncology Industry is Expected to Reach $2.9 Billion by 2028
November 24, 2022 08:08 ET | Research and Markets
Dublin, Nov. 24, 2022 (GLOBE NEWSWIRE) -- The "Global Interventional Oncology Market Size, Share & Industry Trends Analysis Report By Cancer Type (Liver Cancer, Lung Cancer, Kidney Cancer,...
22157.jpg
Global Interventional Oncology Market Analysis Report 2022: A $2.11 Billion Market by 2026 - Forecasts to 2029
November 23, 2022 06:08 ET | Research and Markets
Dublin, Nov. 23, 2022 (GLOBE NEWSWIRE) -- The "Interventional Oncology Global Market - Forecast to 2026" report has been added to ResearchAndMarkets.com's offering. The Interventional Oncology...
researchdrivelogo.jpg
Global Liver Disease Treatment Market Anticipated to Garner $32,028.5 Million, Growing with 11.7% CAGR in the 2021–2028 Timeframe [240-Pages] | Wrap up by Research Dive
October 12, 2022 08:59 ET | Research Dive
New York, USA, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Research Dive has published a new report on the global liver disease treatment market. According to the report, the global market is projected to...
Press news Biocartis Group NV: Biocartis Initiates Commercialization in Europe of HepatoPredict (CE-IVD) Test for Liver Cancer Patients
October 10, 2022 01:00 ET | Biocartis NV
PRESS RELEASE: 10 October 2022, 07:00 CEST Biocartis Initiates Commercialization in Europe of HepatoPredict (CE-IVD) Test for Liver Cancer PatientsHepatoPredict helps identify Hepatocellular...
Persbericht Biocartis Group NV: Biocartis initieert commercialisatie in Europa van HepatoPredict (CE-IVD) test voor leverkankerpatiënten
October 10, 2022 01:00 ET | Biocartis NV
PERSBERICHT: 10 oktober 2022, 07:00 CEST Biocartis initieert commercialisatie in Europa van HepatoPredict (CE-IVD) test voor leverkankerpatiëntenHepatoPredict helpt patiënten met hepatocellulair...
22157.jpg
Global Oncology Nutrition Market Report 2022: A $2.13 Billion Market in 2026 Featuring B. Braun Melsungen, Danone India, Abbott Laboratories, Nestle, Victus
October 06, 2022 06:13 ET | Research and Markets
Dublin, Oct. 06, 2022 (GLOBE NEWSWIRE) -- The "Oncology Nutrition Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.The global oncology nutrition market is...
#OctoberIs4Livers: Rates of Liver Cancers Are Going Up – and Communities of Color Face the Most Risk
October 01, 2022 09:07 ET | Global Liver Institute
Washington, D.C., Oct. 01, 2022 (GLOBE NEWSWIRE) -- Global Liver Institute (GLI) today launches its 5th annual #OctoberIs4Liver education and awareness campaign, which calls attention to liver...
Elevar Logo for Common Use.png
Elevar Therapeutics Announces Camrelizumab Plus Rivoceranib Significantly Prolonged Overall Survival and Progression-Free Survival Versus Sorafenib in Patients With Unresectable Hepatocellular Carcinoma During Phase 3 Trial, a Joint Program With Hengrui Pharma
September 10, 2022 04:00 ET | Elevar Therapeutics
Top-line findings were presented today at the annual European Society for Medical Oncology (ESMO) Congress This is the first positive pivotal trial to show survival benefits with a PD-1 inhibitor...
Elevar Logo for Common Use.png
Elevar Therapeutics Announces Camrelizumab Plus Rivoceranib Significantly Prolonged Overall Survival and Progression-Free Survival Versus Sorafenib in Patients With Unresectable Hepatocellular Carcinoma During Phase 3 Trial, a Joint Program With Hengrui Pharma
September 07, 2022 18:05 ET | Elevar Therapeutics
Top-line findings will be presented Sept. 10 at the annual European Society for Medical Oncology (ESMO) Congress This is the first positive pivotal trial to show survival benefits with a PD-1...